Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have been demonstrated for many 1L mCRPC treatments, including novel agents such as talazoparib plus enzalutamide. However, due to the lack of direct comparisons, it is unclear how new treatments compare to many of those already used in clinical practice, creating challenges when choosing which therapeutic option to recommend to patients.
To help bridge this gap, Elena Castro, MD; the team at Pfizer Inc. (Alexander Niyazov and Jonathan Nazari); and the Value & Evidence team at EVERSANA (Imtiaz A. Samjoo, Jenna Ellis, Samantha Craigie and Anja Haltner) conducted a comprehensive systematic literature review and network meta-analysis (NMA) to estimate the relative treatment effects between talazoparib plus enzalutamide and other therapies for patients with asymptomatic or mildly symptomatic mCRPC in the 1L setting. NMAs allow for the comparison of multiple treatment options simultaneously by combining published evidence. This comprehensive analysis was recently published in The Oncologist, an esteemed oncology journal.
The NMA results showed that talazoparib plus enzalutamide offers a therapeutic benefit over other 1L mCRPC treatments across multiple clinical endpoints. For decision-makers and clinicians, this study highlights the importance of indirect comparison methods, such as NMAs, in guiding healthcare decision-making in the advancing field of metastatic prostate cancer.
For a deeper understanding, access The Oncologist article here.
Author
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…
Jenna is a Manager on the Value & Evidence team at EVERSANA with experience conducting indirect treatment comparisons. Since joining the team in 2022, Jenna has been involved in the development and execution of…
Samantha Craigie holds an MSc in Epidemiology and Biostatistics from the University of Western Ontario. As an Associate Director at EVERSANA in Evidence Synthesis, Samantha has led many global SLR and ITC projects for…
Anja brings over 10 years of academic and industry experience in applied statistical analyses. Anja’s research focuses on population-adjusted indirect treatment comparisons including matching-adjusted indirect comparisons, simulated treatment comparisons, and propensity score matching and…